Biogen Aktie

132,55 EUR +1,50 EUR +1,14 %

02.10.2025

BMN

154,97 USD -0,28 USD -0,18 %

nachbörslich00:00:21

BTT

Biogen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.19,29 Mrd. EUR

KGV13,67Div. Rendite0,00%

WKN789617

ISINUS09062X1037

SymbolBIIB

Biogen Aktien News

Sortieren:Datum Meistgelesen

03.09.25PR NewswireEisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disea...

02.09.25PR Newswire/U P D A T E -- Eisai Inc./

29.08.25PR NewswireFDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

WerbungBiogen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

30.07.25PR NewswireTwo-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

30.07.25PR NewswireNew Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease

30.07.25PR NewswireEarly Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

12.06.25GlobeNewswireDapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

27.05.25GlobeNewswireBiogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

02.04.25GlobeNewswireBiogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

24.03.25GlobeNewswireBiogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

11.03.25GlobeNewswireBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

28.02.25PR NewswireThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

18.02.25GlobeNewswireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N

31.01.25GlobeNewswireUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

27.01.25GlobeNewswireFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

27.01.25PR NewswireFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

23.01.25GlobeNewswireFDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

14.01.25GlobeNewswireFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

14.01.25PR NewswireFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

05.12.24PR Newswire"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

28.11.24PR Newswire"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

19.11.24GlobeNewswireDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

14.11.24PR NewswireEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

14.11.24GlobeNewswireEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

31.10.24GlobeNewswireEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

29.10.24GlobeNewswireBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

29.10.24GlobeNewswireBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer

28.10.24GlobeNewswireMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

27.10.24GlobeNewswireBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

24.10.24GlobeNewswireBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

22.10.24GlobeNewswireBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

09.10.24GlobeNewswireBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

08.10.24GlobeNewswireNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

24.09.24GlobeNewswireUCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

12.09.24GlobeNewswireBiogen Board Appoints Two New Independent Directors

04.09.24GlobeNewswireBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

22.08.24PR NewswireLeqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

31.07.24PR NewswireAlcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

30.07.24GlobeNewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz

30.07.24PR NewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The...

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.